| 產(chǎn)品名稱 |
NCI-H2171 [H2171] |
| 商品貨號 |
B165320 |
| Organism |
Homo sapiens, human |
| Tissue |
lung; derived from metastatic site: pleural effusion |
| Cell Type |
lymphoblast |
| Product Format |
frozen |
| Morphology |
floating clusters |
| Culture Properties |
suspension |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease |
stage E, carcinoma; small cell lung cancer |
| Age |
50 years |
| Gender |
male |
| Ethnicity |
Caucasian |
| Karyotype |
iso(3q) |
| Derivation |
The line was established in April 1989 from a pleural effusion metastasis of a lung. |
| Clinical Data |
50 years
Caucasian
male
The patient received prior chemotherapy and radiation therapy.
The patient was a smoker.
150 pack years |
| Comments |
A lymphoblastoid line from the same patient is available as ATCC CRL-5969. |
| Complete Growth Medium |
HITES medium supplemented with 5% fetal bovine serum
The base medium for this cell line is ATCC-formulated DMEM:F12 Medium Catalog No.30-2006. To make the complete growth medium,add the following components to the base medium- 0.005 mg/ml Insulin
- 0.01 mg/ml Transferrin
- 30nM Sodium selenite (final conc.)
- 10 nM Hydrocortisone (final conc.)
- 10 nM beta-estradiol (final conc.)
- extra 2mM L-glutamine (for final conc. of 4.5 mM)
- 5% fetal bovine serum (final conc.)
|
| Cryopreservation |
Culture medium, 95%; DMSO, 5% |
| Name of Depositor |
AF Gazdar, JD Minna |
| Deposited As |
Homo sapiens |
| Year of Origin |
1989 |
| References |
NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996.
|
